Cervarix

ApprovedBiologic

GSK

Cervarix is one of 130 biologic programs targeting Hepatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Spontaneous AbortionActive, not recruiting

Cervical CancerActive, not recruiting

Hepatitis BActive, not recruiting

PapillomaActive, not recruiting

HepatitisPhase 3

Active, not recruiting

Spontaneous AbortionPreclinical

Active, not recruiting

Cervical CancerApproved

Active, not recruiting

Hepatitis BApproved

Active, not recruiting

PapillomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

380 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Cervarix

GSK

Approved

2 2

Ifex

BBaxter Healthcare Corporation

Phase 3

2 3

Oncovin

EEastern Cooperative Oncology Group

Phase 3

1 4

Velban

EEastern Cooperative Oncology Group

Phase 3

1 5

Blenoxane

SSequus Pharmaceuticals

Phase 3

1 6

Epoetin Beta

Roche

Phase 3

1 7

Zimberelimab

Arcus Biosciences

Phase 3

3 8

SG001

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 9

SYS6002

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

1 10

WX390

SShanghai Jiatan Pharmatech Co., Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Papilloma9 trials

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Completed· GSK logo

GSK·Phase 3·NCT00578227·814 enrolled

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Completed· GSK logo

GSK·Phase 3·NCT00481767·676 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Completed· GSK logo

GSK·Phase 3·NCT01462357·1,079 enrolled

Show 6 more trials

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Completed· GSK logo

GSK·Phase 3·NCT00294047·5,752 enrolled

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Completed· GSK logo

GSK·Phase 3·NCT00122681·18,729 enrolled

A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

Terminated· GSK logo

GSK·Phase 4·NCT00730847·743 enrolled

Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women

Completed· GSK logo

GSK·Phase 3·NCT00337818·770 enrolled

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

Completed· GSK logo

GSK·Phase 3·NCT00196937·667 enrolled

Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults

Completed·UUniversity of Aarhus·Phase 4·NCT01386164·92 enrolled

Immunogenicity7 trials

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Completed· GSK logo

GSK·Phase 3·NCT01627561·148 enrolled

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

Completed· GSK logo

GSK·Phase 2·NCT00546078·116 enrolled

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Completed· GSK logo

GSK·Phase 3·NCT00492544·100 enrolled

Show 4 more trials

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Completed· GSK logo

GSK·Phase 1·NCT00541970·961 enrolled

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

Completed· GSK logo

GSK·Phase 2·NCT00586339·150 enrolled

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Completed· GSK logo

GSK·Phase 4·NCT00534638·34,412 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Completed· GSK logo

GSK·Phase 3·NCT01755689·1,300 enrolled

HPV Vaccine3 trials

Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

Completed· GSK logo

GSK·Phase 3·NCT00811798·92 enrolled

Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Completed· GSK logo

GSK·Phase 2·NCT00518336·433 enrolled

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)

Completed·UUniversity Hospital, Ghent·Phase 4·NCT01914367·12 enrolled

Cervical Cancer2 trials

Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females

Completed· GSK logo

GSK··NCT01101542·3,091 enrolled

FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program

Completed·IInstituto Nacional de Salud Publica, Mexico·Phase 4·NCT03105856·3,000 enrolled

Health Services1 trial

Comparing Health Services Interventions for the Prevention of HPV-related Cancer

Completed·CCHU de Reims·Phase 4·NCT02837926·63 enrolled

11 more indications

Hepatitis1 trial

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Withdrawn· GSK logo

GSK·Phase 3·NCT02082639

Spontaneous Abortion1 trial

Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK

Completed· GSK logo

GSK··NCT01905462·1,046 enrolled

HPV Vaccination1 trial

Evaluation of Long Term Immunity Following HPV Vaccination

Completed·MMurdoch Childrens Research Institute··NCT02276521·200 enrolled

Adolescent1 trial

Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls

Completed·PPublic Health England·Phase 4·NCT00956553·400 enrolled

Hepatitis B1 trial

Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination

Terminated·NNational Institute for Public Health and the Environment (RIVM)·Phase 4·NCT01082861

Immune Response1 trial

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

Completed· GSK logo

GSK·Phase 3·NCT00250276·798 enrolled

Children1 trial

Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Completed·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 1·NCT04301154·25 enrolled

Drug1 trial

Drug Use Investigation for Cervarix®

Completed· GSK logo

GSK··NCT01187927·1,230 enrolled

Infection1 trial

Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women

Completed· GSK logo

GSK·Phase 2·NCT00689741·1,113 enrolled

HPV1 trial

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Completed· GSK logo

GSK·Phase 3·NCT01190176·34 enrolled

Unspecified1 trial

Cervarix Long-term Safety Surveillance

Completed· GSK logo

GSK··NCT01498627·2,945 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Cervarix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cervarix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cervarix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: GSK

Cervarix

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Papilloma9 trials

Immunogenicity7 trials

HPV Vaccine3 trials

Cervical Cancer2 trials

Health Services1 trial

Hepatitis1 trial

Spontaneous Abortion1 trial

HPV Vaccination1 trial

Adolescent1 trial

Hepatitis B1 trial

Immune Response1 trial

Children1 trial

Drug1 trial

Infection1 trial

HPV1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News